Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UV1 vaccine+ leukine · 1 trial · 7 indications
Progression-free survival (PFS) per Modified Response Evaluation Criteria in Solid Tumors (RECIST) as determined by blinded independent central review (BICR) assessed by radiologic assessments
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Ipilimumab and nivolumab + UV1 |
| Arm B | ACTIVE_COMPARATOR | Ipilimumab and nivolumab |
| Name | Type | Description |
|---|---|---|
| UV1 vaccine + leukine | BIOLOGICAL | The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms. |
| ipilimumab | BIOLOGICAL | The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging. |
| nivolumab | BIOLOGICAL | The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging. |
Inclusion Criteria: * Histologically and/or cytologically confirmed malignant pleural mesothelioma. * Unresectable disease * Measurable disease, defined as at least 1 lesion (measurable) that can be accurately assessed at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) and ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
UV1 vaccine + leukine is an investigational cancer treatment being studied in oncology. It is currently in Phase 2 clinical development for cancer, specifically being evaluated in patients with malignant mesothelioma. The drug is being tested as a combination therapy with other agents in a clinical trial setting.
UV1 vaccine + leukine is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate this investigational cancer treatment in patients with malignant mesothelioma.
UV1 vaccine + leukine is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 2 trial is active but not recruiting participants.
UV1 vaccine + leukine is being studied in one active Phase 2 clinical trial with the identifier NCT04300244. This trial is evaluating nivolumab and ipilimumab with or without UV1 vaccination as second line treatment in patients with malignant mesothelioma. The trial has enrolled 118 participants across Australia, Denmark, Norway, Spain, and Sweden.
Yes, UV1 vaccine + leukine is also known as UV1 vaccine + leukine. These names refer to the same investigational cancer treatment being developed by Bristol-Myers Squibb Company for the treatment of malignant mesothelioma.